Bladder Control |
Urinary Incontinence |
Clinical Trial: Combination Chemotherapy in Treating Patients With Bladder Cancer
This study is currently recruiting patients.
Purpose
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Randomized phase III trial to compare different combination chemotherapy regimens in treating patients who have advanced bladder cancer.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| stage III bladder cancer stage IV bladder cancer transitional cell carcinoma of the bladder | Drug: cisplatin Drug: doxorubicin Drug: filgrastim Drug: gemcitabine Drug: paclitaxel Procedure: biological response modifier therapy Procedure: chemotherapy Procedure: colony-stimulating factor therapy Procedure: cytokine therapy | Phase III |
MedlinePlus related topics: Bladder Cancer; Cancer
Genetics Home Reference related topics: bladder cancer
Study Type: Interventional
Study Design: Treatment
Official Title: Phase III Randomized Study of Adjuvant Doxorubicin and Gemcitabine Followed By Paclitaxel and Cisplatin Versus Adjuvant Cisplatin and Gemcitabine in Patients With Completely Resected Locally Advanced Transitional Cell Carcinoma of the Bladder
OBJECTIVES: Primary
- Compare the survival of patients with completely resected locally advanced transitional cell carcinoma of the bladder treated with adjuvant doxorubicin and gemcitabine followed by paclitaxel and cisplatin vs adjuvant cisplatin and gemcitabine.
Secondary
- Compare the toxicity profiles of these regimens in these patients.
OUTLINE: This is a randomized study. Patients are stratified according to primary tumor status (<T4 vs T4), number of positive lymph nodes (0 or unknown vs 1-5 vs >5), and number of dissected nodes (0-10 or unknown vs > 10). Patients are randomized to one of two treatment arms.
- Arm I: Patients receive adjuvant gemcitabine IV over 30 minutes on days 1, 8, and 15 and cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
- Arm II: Patients receive adjuvant doxorubicin IV over 45 minutes followed by gemcitabine IV over 2 hours on day 1. Patients also receive filgrastim (G-CSF) subcutaneously (SC) daily on days 3-10. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Beginning 14 days after the completion of doxorubicin and gemcitabine, patients receive paclitaxel IV over 3 hours and cisplatin IV over 20-30 minutes on day 1. Patients also receive G-CSF SC daily on days 3-10 or 4-11. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 18 months, every 6 months for 18 months, and then annually thereafter.
PROJECTED ACCRUAL: A total of 800 patients will be accrued for this study within 6 years.
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
DISEASE CHARACTERISTICS:
- Histologically confirmed transitional cell carcinoma of the bladder
- Any T, N+, M0 OR
- T3a-4a, N0, M0
- At least 6 weeks but no more than 3 months since prior complete resection of bladder
- Cystoprostatectomy plus pelvic lymph node dissection in males
- Cystectomy/total abdominal hysterectomy/bilateral salpingo-oophorectomy plus pelvic lymph node dissection in females
- Negative surgical margins
- Carcinoma in situ allowed
- No partial cystectomy or transurethral bladder tumor resection as definitive loco-regional therapy
- Prostate cancer detected in resected specimen allowed if post-operative PSA is no more than 0.05 mg/dL
- No metastatic or recurrent disease by post-operative chest x-ray and CT scan of abdomen and pelvis
PATIENT CHARACTERISTICS: Age:
- 18 and over
Performance status:
- ECOG 0-1
Life expectancy:
- Not specified
Hematopoietic:
- Absolute neutrophil count ≥ 1,500/mm^3
- Platelet count ≥ 150,000/mm^3
Hepatic:
- Bilirubin ≤ 1.5 times upper limit of normal (ULN)
- Alkaline phosphatase ≤ 2 times ULN
- AST ≤ 2 times ULN
Renal:
- Creatinine ≤ 1.5 mg/dL OR
- Creatinine clearance ≥ 60 mL/min
Cardiovascular:
- Normal cardiac function by history, physical exam, or chest radiograph
- Left ventricular ejection fraction at least 50% by radionuclide ventriculogram or echocardiogram, for prior cardiac disease
- No New York Heart Association class III or IV heart disease
- No serious cardiac arrhythmias including first-, second-, and third-degree heart block
Other:
- Negative pregnancy test
- No uncontrolled infection
- No other active cancer within the past 5 years except non-melanoma skin cancer or curatively treated carcinoma in situ of the cervix
PRIOR CONCURRENT THERAPY: Biologic therapy:
- Not specified
Chemotherapy:
- No prior systemic chemotherapy
Endocrine therapy:
- Not specified
Radiotherapy:
- No prior radiotherapy to bladder
Surgery:
- See Disease Characteristics
Location and Contact Information
Alabama
Northeast Alabama Regional Medical Center, Anniston, Alabama, 36207, United States; Recruiting
California
Naval Medical Center - San Diego, San Diego, California, 92134-3202, United States; Recruiting
Rebecca and John Moores UCSD Cancer Center, La Jolla, California, 92093-0658, United States; Recruiting
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, 90048, United States; Recruiting
UCSF Comprehensive Cancer Center, San Francisco, California, 94115, United States; Recruiting
Veterans Affairs Medical Center - San Diego, San Diego, California, 92161, United States; Recruiting
Veterans Affairs Medical Center - San Francisco, San Francisco, California, 94121, United States; Recruiting
Delaware
CCOP - Christiana Care Health Services, Newark, Delaware, 19713, United States; Recruiting
District of Columbia
Lombardi Cancer Center at Georgetown University Medical Center, Washington, District of Columbia, 20007, United States; Recruiting
Walter Reed Army Medical Center, Washington, District of Columbia, 20307-5001, United States; Recruiting
Florida
Broward General Medical Center, Fort Lauderdale, Florida, 33316, United States; Recruiting
CCOP - Mount Sinai Medical Center, Miami Beach, Florida, 33140, United States; Recruiting
Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, 33021, United States; Recruiting
Palm Beach Cancer Institute - West Palm Beach, West Palm Beach, Florida, 33401, United States; Recruiting
Illinois
CCOP - Evanston, Evanston, Illinois, 60201, United States; Recruiting
CCOP - Illinois Oncology Research Association, Peoria, Illinois, 61615-7828, United States; Recruiting
Louis A. Weiss Memorial Hospital, Chicago, Illinois, 60640, United States; Recruiting
MBCCOP - University of Illinois at Chicago, Chicago, Illinois, 60612, United States; Recruiting
University of Chicago Cancer Research Center, Chicago, Illinois, 60637-1470, United States; Recruiting
Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, 60612, United States; Recruiting
West Suburban Center for Cancer Care, River Forest, Illinois, 60305, United States; Recruiting
Indiana
CCOP - Northern Indiana CR Consortium, South Bend, Indiana, 46601, United States; Recruiting
Fort Wayne Medical Oncology and Hematology, Incorporated, Fort Wayne, Indiana, 46885-5099, United States; Recruiting
Iowa
Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, 52242-1009, United States; Recruiting
Kentucky
Baptist Hospital East - Louisville, Louisville, Kentucky, 40207, United States; Recruiting
Maryland
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, 21201, United States; Recruiting
Massachusetts
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States; Recruiting
UMASS Memorial Cancer Center - University Campus, Worcester, Massachusetts, 01655, United States; Recruiting
Michigan
CCOP - Grand Rapids, Grand Rapids, Michigan, 49503, United States; Recruiting
Lakeland Cancer Care Center at Lakeland Hospital - St. Joseph, Saint Joseph, Michigan, 49085, United States; Recruiting
Minnesota
University of Minnesota Cancer Center, Minneapolis, Minnesota, 55455, United States; Recruiting
Veterans Affairs Medical Center - Minneapolis, Minneapolis, Minnesota, 55417, United States; Recruiting
Missouri
CCOP - Kansas City, Kansas City, Missouri, 64131, United States; Recruiting
Ellis Fischel Cancer Center at University of Missouri - Columbia, Columbia, Missouri, 65203, United States; Recruiting
Missouri Baptist Cancer Center, Saint Louis, Missouri, 63131, United States; Recruiting
Siteman Cancer Center at Barnes-Jewish Hospital, Saint Louis, Missouri, 63110, United States; Recruiting
Veterans Affairs Medical Center - Columbia (Truman Memorial), Columbia, Missouri, 65201, United States; Recruiting
Nebraska
UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska, 68198-7680, United States; Recruiting
Nevada
CCOP - Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, 89106, United States; Recruiting
Veterans Affairs Medical Center - Las Vegas, Las Vegas, Nevada, 89106, United States; Recruiting
New Hampshire
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, 03756-0002, United States; Recruiting
New Jersey
Cancer Institute of New Jersey at the Cooper University Hospital, Camden, New Jersey, 08103, United States; Recruiting
New York
CCOP - North Shore University Hospital, Manhasset, New York, 11030, United States; Recruiting
CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C., East Syracuse, New York, 13057, United States; Recruiting
Lipson Cancer and Blood Center at Rochester General Hospital, Rochester, New York, 14621, United States; Recruiting
Memorial Sloan-Kettering Cancer Center, New York, New York, 10021, United States; Recruiting
Mount Sinai Medical Center, New York, New York, 10029, United States; Recruiting
New York Weill Cornell Cancer Center at Cornell University, New York, New York, 10021, United States; Recruiting
North Shore University Hospital, Manhasset, New York, 11030, United States; Recruiting
Queens Cancer Center of Queens Hospital, Jamaica, New York, 11432, United States; Recruiting
Roswell Park Cancer Institute, Buffalo, New York, 14263-0001, United States; Recruiting
SUNY Upstate Medical University Hospital, Syracuse, New York, 13210, United States; Recruiting
Veterans Affairs Medical Center - Buffalo, Buffalo, New York, 14215, United States; Recruiting
Veterans Affairs Medical Center - Syracuse, Syracuse, New York, 13210, United States; Recruiting
North Carolina
Cape Fear Valley Medical Center, Fayetteville, North Carolina, 28302-2000, United States; Recruiting
CCOP - Southeast Cancer Control Consortium, Goldsboro, North Carolina, 27534-9479, United States; Recruiting
Comprehensive Cancer Center at Moore Regional Hospital, Pinehurst, North Carolina, 28374, United States; Recruiting
Comprehensive Cancer Center at Wake Forest University, Winston Salem, North Carolina, 27157-1082, United States; Recruiting
Duke Comprehensive Cancer Center, Durham, North Carolina, 27710, United States; Recruiting
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, 27599-7295, United States; Recruiting
NorthEast Oncology Associates - Concord, Concord, North Carolina, 28025, United States; Recruiting
Veterans Affairs Medical Center - Asheville, Asheville, North Carolina, 28805-9913, United States; Recruiting
Veterans Affairs Medical Center - Durham, Durham, North Carolina, 27705, United States; Recruiting
Zimmer Cancer Center at New Hanover Regional Medical Center, Wilmington, North Carolina, 28402-9025, United States; Recruiting
Ohio
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University, Columbus, Ohio, 43210-1240, United States; Recruiting
Oklahoma
Oklahoma University Medical Center, Oklahoma City, Oklahoma, 73104, United States; Recruiting
Pennsylvania
Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, 15224, United States; Recruiting
Rhode Island
Miriam Hospital at Lifespan, Providence, Rhode Island, 02906, United States; Recruiting
Texas
Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, 75390-8852, United States; Recruiting
Veterans Affairs Medical Center - Dallas, Dallas, Texas, 75219, United States; Recruiting
Vermont
Vermont Cancer Center at University of Vermont, Burlington, Vermont, 05401-3498, United States; Recruiting
Virginia
Martha Jefferson Hospital, Charlottesville, Virginia, 22902, United States; Recruiting
MBCCOP - Massey Cancer Center, Richmond, Virginia, 23298-0037, United States; Recruiting
Oncology and Hematology Associates of Southwest Virginia, Incorporated - Roanoke, Roanoke, Virginia, 24014, United States; Recruiting
Virginia Oncology Associates - Norfolk, Norfolk, Virginia, 23502, United States; Recruiting
West Virginia
St. Mary's Medical Center, Huntington, West Virginia, 25701, United States; Recruiting
Dean F. Bajorin, MD, Study Chair, Memorial Sloan-Kettering Cancer Center
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database
Record last reviewed: October 2004
Last Updated: April 5, 2005
Record first received: April 10, 2001
ClinicalTrials.gov Identifier: NCT00014534
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 8, 2005

Not Signed In -


